Company profile

Crispr Therapeutics AG

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc.

More news about Crispr Therapeutics AG

05.03.2024 17:00

Business wind down and take off for listed Swiss startups

Please login or
register to use the
awards follow feature
17.11.2023 13:00

Green light for world’s first CRISPR gene-edited therapy

Please login or
register to use the
awards follow feature
28.03.2023 10:48

Up to $230 million for CRISPR Therapeutics

Please login or
register to use the
awards follow feature
18.10.2016 19:01

CRISPR Therapeutics Announces Pricing of Initial Public Offering

Please login or
register to use the
awards follow feature
21.09.2016 11:55

CRISPR Therapeutics files for $90M IPO

Please login or
register to use the
awards follow feature
27.06.2016 09:06

CRISPR Therapeutics Raises Additional $38M

Please login or
register to use the
awards follow feature
21.12.2015 14:38

Bayer is investing USD 335 million in an alliance with CRISPR Therapeutics

Please login or
register to use the
awards follow feature
27.10.2015 08:55

Lucrative partnering deal for CRISPR

Please login or
register to use the
awards follow feature
30.04.2015 16:39

CRISPR Therapeutics Raises Additional $64 Million

Please login or
register to use the
awards follow feature
28.04.2014 08:40

CRISPR Therapeutics raises $25 million in Series A financing

Please login or
register to use the
awards follow feature
Crispr Therapeutics AG

Founded
2013

Kanton
Zug


LinkedIn

Twitter
@crisprtx

Homepage

rss